United Therapeutics (NASDAQ:UTHR) CEO Sells $1,712,880.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $428.22, for a total value of $1,712,880.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at $55,668.60. This trade represents a 96.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $438.18 on Thursday. The business’s 50-day moving average price is $350.60 and its two-hundred day moving average price is $317.22. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $442.01. The company has a market capitalization of $19.77 billion, a P/E ratio of 17.10, a price-to-earnings-growth ratio of 6.39 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.85 EPS. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Oppenheimer boosted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an “outperform” rating and a $569.00 price objective for the company. Cantor Fitzgerald upped their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Jefferies Financial Group upped their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company upped their price target on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $449.57.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of UTHR. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics in the second quarter valued at about $29,000. SVB Wealth LLC bought a new stake in shares of United Therapeutics in the 1st quarter worth approximately $32,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.